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Summary
 
A striking feature of the T cell receptor (TCR) 
 
b
 
 chain structure is the large FG loop that pro-
trudes freely into the solvent on the external face of the C
 
b
 
 domain. We have already shown
that a transgene-encoded V
 
b
 
8.2
 
1
 
 TCR 
 
b
 
 chain lacking the complete C
 
b
 
 FG loop supports
normal development and function of conventional 
 
a
 
/
 
b
 
 T cells. Thus, the FG loop is not abso-
lutely necessary for TCR signaling. However, further analysis has revealed that a small popula-
tion of 
 
a
 
/
 
b
 
 T cells coexpressing NK1.1 are severely depleted in these transgenic mice. The few
remaining NK1.1 T cells have a normal phenotype but express very low levels of TCR. We find
that the TCR V
 
b
 
8.2
 
1
 
 chain lacking the C
 
b
 
 FG loop cannot pair efficiently with the invariant
V
 
a
 
14-J
 
a
 
281 TCR 
 
a
 
 chain commonly expressed by this T cell family. Consequently, fewer
NK1.1 T cells develop in these mice. Our results suggest that expression of the V
 
a
 
14
 
1
 
 TCR 
 
a
 
chain is particularly sensitive to TCR-
 
b
 
 conformation. Development of NK1.1 T cells appears to
need a TCR-
 
b
 
 conformation dependent on the presence of the C
 
b
 
 loop that is not necessarily
required for assembly and function of TCRs on most 
 
a
 
/
 
b
 
 T cells.
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A
 
ll crystal structures of the TCR 
 
b
 
 chain reported to date
have shown that the constant and variable domains are
closely associated, with a large, solvent-exposed loop of 14
amino acids protruding on the external face of the C
 
b
 
 do-
main (1–4). The location and size of this loop (almost half
of an Ig domain) suggested that it could be the crucial link
between TCR-
 
a
 
/
 
b
 
 recognition of antigen and transmis-
sion of signals by the invariant CD3 (1, 4, 5). To study its
function, we recently generated mice transgenic for a TCR
 
b
 
 chain lacking the complete C
 
b
 
 FG loop. The TCR 
 
b
 
chain (V
 
b
 
8.2-J
 
b
 
2.1) chosen for mutagenesis has been crys-
tallized (1); it was cloned from T cell hybridoma 14.3.d,
which expresses a TCR 
 
a
 
 chain (V
 
a
 
4-J
 
a
 
47) and recognizes
a PR8 influenza hemagglutinin peptide, HA 110–119, pre-
sented by the I-E
 
d
 
 MHC molecule (6). Surprisingly, we
found that development and function of conventional 
 
a
 
/
 
b
 
T cells was normal in mice transgenic for a TCR 
 
b
 
 chain
lacking the C
 
b
 
 FG loop. Thus, the C
 
b
 
 FG loop is not ab-
solutely required for transmitting the signal of antigen rec-
ognition by the TCR (7).
Further analysis revealed that a small population of 
 
a
 
/
 
b
 
T cells coexpressing NK1.1 is drastically diminished in these
mice. Many features (8), including development, functional
properties, and TCR repertoire, distinguish this latter popula-
tion from conventional T cells. Development of NK1.1 T
cells requires expression of the 
 
b
 
2 
 
microglobulin–associated,
class Ib–like CD1d1 molecule (9, 10), which can restrict their
response to lipid ligands such as glycosylphosphatidylinositols
or glycosylceramides (11, 12). NK1.1 T cells can readily pro-
duce large amounts of cytokines upon activation (13), and
they have been implicated in tumor rejection (14, 15) and
may also play a regulatory role in autoimmune manifestations
(16–18). NK1.1 T cells express a limited V
 
b
 
 repertoire highly
skewed toward V
 
b
 
8.2, V
 
b
 
7, and V
 
b
 
2 (8), and in transgenic
mice expressing single V
 
b
 
s such as V
 
b
 
3 and V
 
b
 
8.1, NK1.1
T cell development is totally abrogated (19). Furthermore,
 
z
 
80% of NK1.1 T cells express an invariant TCR 
 
a
 
 chain
(V
 
a
 
14-J
 
a
 
281) (20, 21) that is required for their develop-
ment (15).
In this study, we present evidence that the V
 
b
 
8.2 TCR
 
b
 
 chain lacking the complete C
 
b
 
 FG loop cannot pair effi-
ciently with the canonical V
 
a
 
14
 
1
 
 TCR 
 
a
 
 chain. Conse-
quently, NK1.1 T cell development is severely impaired.
 
Materials and Methods
 
TCR-
 
b
 
 Mutagenesis.
 
The wild-type TCR 
 
b
 
 chain (V
 
b
 
8.2-
J
 
b
 
2.1) cDNA was used as a template for mutagenesis. Deletion of
the 14 nucleotides forming the C
 
b
 
 FG loop has been described
(7). Transgenic vectors have also been described previously (22).
 
Transfection of Cell Lines.
 
Packaging cell lines GP
 
1
 
E-86 (23)
were transfected with retroviral vector LXSN expressing the
V
 
b
 
8.2-J
 
b
 
2.1
 
1
 
 TCR-
 
b
 
 or 
 
b
 
-loop
 
2
 
 chain or LXSP expressing the
V
 
a
 
4-J
 
a
 
47
 
1
 
 or V
 
a
 
14-J
 
a
 
281
 
1
 
 TCR 
 
a
 
 chain cDNA. The TCR 
 
a
 
chain (V
 
a
 
14-J
 
a
 
281) was cloned from NK1.1 
 
a
 
/
 
b
 
1
 
 T cell hy- 
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bridoma total RNA provided by R. MacDonald (Ludwig Institute
for Cancer Research, Lausanne, Switzerland). After appropriate se-
lection of the packaging cells, the infectious supernatants were used
to infect TCR
 
2
 
 hybridomas (24) as previously described (25). The
TCR-
 
b
 
 or 
 
b
 
-loop
 
2
 
 chain was first introduced into the hybridomas
and, after neomycin selection (G418; 1 mg/ml), these cells were su-
perinfected with TCR 
 
a
 
 chain by culturing them on packaging
lines producing LXSP TCR-
 
a
 
 V
 
a
 
4-J
 
a
 
47 or V
 
a
 
14-J
 
a
 
281. The hy-
bridomas were then maintained in IMDM supplemented with 2%
FCS, neomycin, and puromycin (10 
 
m
 
g/ml). TCR expression was
tested by FACS™ as early as 4 d after selection. Stable transfectants
were maintained in G418 and puromycin-containing medium.
 
TCR Immunoprecipitation and Western Blot Analysis.
 
Hybrid-
omas were lysed at 2 
 
3
 
 10
 
7
 
 cells/ml in 1% Triton X-100 (Bio-Rad
Labs.), 150 mM NaCl, 20 mM Tris/HCl, and 5 mM EDTA, pH
7.5, buffer containing complete protease inhibitors (Boehringer
Mannheim) for 30 min at 4
 
8
 
C. Lysates cleared of cell debris were
immunoprecipitated with purified mAb F23.1 (2 
 
m
 
g/ml) and pro-
tein G–Sepharose (Pharmacia). After washing with lysis buffer and
PBS, the lyophilized pellets were resuspended in reducing SDS
buffer, loaded on a 4–12% Bis-Tris precast gel (Novex), and trans-
ferred onto nitrocellulose membrane Hybond-C extra (Amersham).
Blots were probed in PBS 6% blotting blocker nonfat milk (Bio-
Rad Labs.) and 0.2% Tween with purified mAb H58 (anti-C
 
a
 
),
followed by goat anti–hamster horseradish peroxidase–labeled mAb
(Southern Biotechnology Associates, Inc.) or biotinylated F23.1
(anti-V
 
b8) mAb followed by streptavidin–horseradish peroxi-
dase (Southern Biotechnology Associates, Inc.). The proteins
were detected with a chemiluminescent detection system (Pierce
Chemical Co.).
Mice. BALB/c and C56BL/6 mice were purchased from
IFFA-Credo. The TCR-b knockout mice have been described
(26) and were bred in our specific pathogen–free animal facility
with the TCR-b or TCR b-loop2 transgenic mice.
Cell Suspension, Flow Cytometry, and Antibodies. Cell suspensions
from thymi were depleted of CD81 T cells with anti-CD8 31M
antibody (27) and complement treatment (Cedarlane Labs.), and
liver cells were simply ficolled to eliminate red cells before immu-
nofluorescence stainings, performed as previously described (28).
Flow cytometric analyses were performed on a FACSCalibur™
equipped with CELLQuest software (Becton Dickinson). The re-
agents used were mAbs 145-2C11 (anti-CD3e), NKR-P1C (anti-
NK1.1), H57-597 (anti-Cb), RM4-5 (anti-CD4), IM7 (anti-CD44,
Pgp-1), TM-b1 (anti–IL-2R b chain), MEL-14 (anti-CD62L) (all
seven mAbs purchased from PharMingen), biotinylated F23.1
(anti-Vb8.1,2,3), and second step reagent streptavidin–allophy-
cocyanin (Molecular Probes, Inc.).
Single-Cell Reverse Transcriptase–PCR. Single NK1.11CD31 cells
were sorted into polycarbonated 96-well plates (one cell per well
in 5 ml of PBS) and immediately frozen on dry ice and stored at
2708C. To prepare cDNA, the plate was heated up to 658C for
1 min before adding into each well 10 ml of the reverse tran-
scriptase (RT)-PCR mix (reverse transcriptase Superscript II;
GIBCO BRL) for 1 h at 428C under standard reaction condi-
tions. After heat inactivation of the enzyme (2 min at 958C), DNA
amplification was carried out as described (29). 75 ml of a PCR
mix containing Taq polymerase and the primers necessary for
DNA amplification of the Va141 TCR a chain (59 Va14 CTA-
AGCACAGCACGCTGCACA [reference 20]; 39 C a ATG-
GATCCTCAACTGGACCACAGCCTCA) and Vb8.21 TCR
b chain (59 Vb8.2 CTTGAGCTCAAGATGGGCTCCAGGCT-
CTTC; 39 Jb2.1 CTGCTCAGCATAACTCCCCCG) were added
to the wells for the first round of PCR (30 cycles). An aliquot from
this PCR (1 ml) was used for a second round of PCR (35 cycles)
to individually reamplify the Va141 TCR a chain or Vb8.21
TCR b chain using the same specific primers.
Results and Discussion
To avoid any influence of the endogenous b locus on the
expression of the mutated b chain, mice transgenic for the
Vb8.21 TCR b chain lacking the Cb FG loop (b-loop2)
were backcrossed to TCR-b2/2 mice (26). T cell develop-
ment in these mice was compared with that in wild-type
Vb8.21 TCR b chain transgenic mice, also with a b2/2
background. As described in our previous study (7), periph-
eral T cells from mice transgenic for the TCR b or b-loop2
chain express equal levels of the TCR–CD3 complex, and
whereas the anti-Vb8 F23.1 mAb recognizes all T cells, the
Cb-specific H57 mAb does not stain cells expressing the
TCR b-loop2 chain (Fig. 1; reference 4). It is worth point-
ing out that in the absence of the Cb FG loop, the anti-
CD3e 2C11 mAb stains better, suggesting that the epitope
recognized is more accessible, a result that might not be
surprising, as one of the CD3e chains is physically adjacent
to the b chain in the TCR–CD3 complex (5).
We consistently found that TCR b-loop2 transgenic mice
have significantly fewer NK1.1 a/b1 T cells in the thymus,
liver, and spleen (data not shown) in comparison to TCR-b
transgenic mice or wild-type littermates (Fig. 2). Thus, a mu-
tation in the Cb domain can notably alter development of
NK1.1 a/b T cells. This result was puzzling, considering that
conventional a/b T cells are normal in TCR b-loop2 trans-
genic mice (7). Furthermore, the mutated TCR b chain uses
Vb8.2, a variable region that is usually expressed by .40% of
NK1.1 a/b T cells (30). Hence, monoclonal expression of
Figure 1. T cells expressing the Vb8.21 TCR b chain lacking the FG
loop cannot be stained with the Cb-specific H57 mAb. LN cell suspen-
sions from TCR-b and b-loop2 transgenic mice were stained with anti-
CD3 together with anti-Vb8 or anti-Cb mAb.1359 Degermann et al. Brief Definitive Report
the wild-type Vb8.21 TCR b chain allows NK1.1 T cell de-
velopment comparable to that of nontransgenic littermates.
Characteristically, NK1.1 T cells express intermediate levels
of TCR (8). Interestingly, in TCR b-loop2 transgenic mice,
TCR expression on the few remaining NK1.1 T cells is even
lower than in control animals; these cells express about four
times less TCR than do those in wild-type b-transgenic mice
(Fig. 3). Otherwise, NK1.1 T cells in b-loop2 transgenic
mice express normal levels of CD4 and are CD441CD62
ligand (L)2 and IL-2Rb1, as expected for this T cell popula-
tion (8). CD1d, a b2 microglobulin–associated molecule re-
quired for NK1.1 T cell development (9, 10), is also ex-
pressed at normal levels in TCR b-loop2 transgenic mice
(data not shown).
To determine if development of NK1.1 a/b1 T cells
could be rescued by the expression of endogenous b chains,
as has been described for other TCR-b transgenic mice
(19), we studied NK1.1 T cell frequency in TCR b-loop2
transgenic mice on a b1/2 background. We have already
observed that in these mice, inhibition of b rearrangements
via allelic exclusion is not total, and z10–20% of peripheral
T cells can express endogenous b chains (data not shown).
NK1.1 a/b1 T cells expressing endogenous b and b-loop2
chains could be distinguished by the Cb-specific H57 mAb,
which cannot stain T cells expressing the mutated b chain
(Fig. 1). As shown in Fig. 4, expression of endogenous b
chains can rescue NK1.1 T cell development to a certain
extent. NK1.1 Cb1 cells appear in the livers of TCR b-loop2
transgenic mice on a b1/2 background. Yet these cells only
account for about one-third of the whole NK1.1 T cell
population. The NK1.1 Cb2 T cells are still predominant.
There are two populations of NK1.1 Vb81 cells, which ex-
press either intermediate or low TCR levels in TCR b-loop2
transgenic mice on a b1/2 background. Interestingly, ex-
pression of endogenous b chains accounts for most of the
NK1.1 T cells expressing intermediate TCR levels. Thus,
expression of endogenous b chains did rescue some NK1.1
T cell development and restore TCR expression to interme-
diate levels. This result strongly suggested that the Cb FG
loop is needed for efficient TCR assembly in NK1.1 T cells.
As most NK1.1 a/b1 T cells express an invariant Va14-
Ja281 TCR a chain (20, 21), and the mutant TCR b chain
is expressed at normal levels by conventional a/b T cells
(Fig. 1) but not by NK1.1 T cells (Fig. 3), we assessed
whether the mutant Vb8.21 TCR b chain could still pair
with the Va141 TCR a chain. TCR2 hybridomas were
Figure 2. Decreased amount of
NK1.1 T cells in TCR b-loop2
transgenic mice. Cell suspension from
thymi previously depleted of CD81
cells and livers from nontransgenic
littermates (WT) or TCR-b or
b-loop2 transgenic mice were dou-
ble stained with anti-NK1.1 together
with anti-Cb (to stain all T cells in
WT mice) or anti-Vb8 (which stains
all T cells in transgenic mice) anti-
bodies. Numbers express the per-
centages of total adjacent gated dots.
Figure 3. The remaining NK1.1 T
cells in TCR b-loop2 transgenic mice
have a normal phenotype. Liver cell
suspensions from TCR-b or b-loop2
transgenic mice were triple stained
with anti-NK1.1, anti-Vb8, and ei-
ther anti-CD4 or anti-CD44 or anti-
CD62L or anti–IL-2Rb mAbs. Histo-
grams represent NK1.11Vb81 gated
events. Numbers in parentheses repre-
sent the mean fluorescence intensity of
Vb8 staining. Negative controls of
Vb8 staining are shown (dashed lines).1360 TCR Cb Mutation Affecting NK1.1 T Cell Development
transfected with cDNAs coding for either the wild-type
TCR b or b-loop2 chain together with the Va141 TCR
a chain or Va41 TCR a chain (the original partner of the
nonmutated b chain) cDNAs. As shown in Fig. 5 A, the
TCR b-loop2 chain clearly pairs with and is expressed on
the cell surface with the Va41 TCR a chain but is barely
detectable on the cell surface with the Va141 TCR a
chain. In contrast, the wild-type TCR b chain is expressed
on the cell surface with both a chains (Fig. 5). However,
the Va141 TCR is expressed at lower levels than is the
Va41 TCR. This observation may reflect the in vivo situa-
tion in which a TCR on NK1.1 T cells is expressed at lower
levels than on conventional a/b T cells. To assess whether
impaired cell surface expression of the TCR wild-type b
and b-loop2 chain together with the Va141 TCR a chain
is due to a problem of pairing, TCRs from the transfectants
were immunoprecipitated with anti-Vb8 mAb. As can be
seen in Fig. 5 B, the TCR a chain can be coimmunopre-
cipitated with the TCR b chain in all transfectants express-
ing the TCR on the cell surface. In contrast, the Va141
TCR a chain cannot be coimmunoprecipitated with the
mutant b chain in detectable amounts. This result implies
that the Va141 TCR a chain pairs very poorly with the
Vb81 TCR b chain lacking the Cb FG loop. It is worth
pointing out that in the hybridomas producing the wild-
type b and Va141 chains, many fewer assembled a/b dimers
can be immunoprecipitated compared with control Vb8.2/
Va4 dimers. This latter result suggests that mere physical
constraints on the assembly of the b chain with the Va141
TCR a chain exist and is consistent with the low TCR ex-
pression on normal NK1.1 T cells.
Next, we assessed whether the NK1.1 a/b1 T cells that
do develop in TCR b-loop2 transgenic mice express the
Va141 TCR a chain by performing RT-PCR on single
NK1.1 CD31 T cells sorted from TCR-b and b-loop2
transgenic mice. As summarized in Table I, the frequency
of NK1.1 T cells expressing Va14 is not significantly de-
creased in TCR b-loop2 transgenic mice in comparison to
wild-type TCR-b transgenic animals. One has to keep in
Figure 4. Expression of endogenous TCR b chains can rescue some
NK1.1 T cell development. Liver cell suspensions from TCR b, b-loop2
transgenic with a b2/2 background (b-loop2 b-endo2/2) or b2/1 back-
ground (b-loop2 b-endo2/1) were triple stained with anti-NK1.1, anti-
Cb, and anti-Vb8 mAbs. Numbers in dot plots are percentages of the
total adjacent gated dots. Histograms represent expression of Cb (in
b-loop2 transgenic mice with a b2/2 or b2/1 background) for the
NK1.11 gated population expressing either intermediate (NK1.11Vb8int)
or low levels of TCR (NK1.11Vb8low).
Figure 5. Inefficient pairing of the Va141 TCR a chain with the Vb8.21 TCR b chain lacking the complete Cb FG loop. (A) TCR2 hybridomas
were transfected with either the Vb8.21 wild-type TCR b or b-loop2 chain, together with the Va141 TCR a chain or Va41 TCR a chain. Stable
transfectants were stained with biotinylated anti-CD3 mAb, followed by streptavidin–allophycocyanin. Stainings of cells transfected with only the TCR
b or b-loop2 chain are shown as controls. Numbers in parentheses represent the mean fluorescence intensities of CD3 staining. (B) TCRs of transfected
hybridomas or Vb81 T hybridoma control (A5) (8.0, 8.0, 10.0, 14.0, 20.0, 20.0, and 8.0 3 107 cells per lane, respectively, from left to right) were im-
munoprecipitated with anti-Vb8 mAb (F23.1), electrophoresed on a 4–12% gel in reducing conditions, and blotted with anti-Ca (H58) or anti-Vb8
mAb as described in Materials and Methods. Numbers represent protein molecular mass (kD).1361 Degermann et al. Brief Definitive Report
mind, however, that there are few NK1.1 T cells in the
mutant mice, and these express much lower levels of TCR
(Fig. 3). This, together with biochemical data, strongly sug-
gests that in TCR b-loop2 transgenic mice, both the im-
paired development of NK1.1 T cells and their weak TCR
expression is due to the physical constraints on the assembly
of the b chain lacking the Cb FG loop with the Va141
TCR a chain.
We have previously shown that in conventional T cells
expressing Vb8.2, deletion of the Cb FG loop has no effect
on Va (7) and Ja repertoire usage (our unpublished data).
This result suggested that no drastic conformational
changes in the TCR b chain were created by the mutation.
However, in this study we clearly show that expression of
the Va141 a chain is sensitive to deletion of the Cb FG
loop. Therefore, deletion of the Cb FG loop must create
some subtle change in TCR b chain conformation. It
seems that expression of the Va141 a chain does not allow
much structural flexibility of the TCR, as it is particularly
sensitive to TCR b chain conformation. Its expression
might impose stringent constraints on a/b assembly. This
could at least partially explain why the Vb repertoire of
NK1.1 T cells is relatively limited (30). Pairing with the ap-
parently conformation-sensitive Va14-Ja281 TCR a chain
could be the initial pressure on Vb usage in NK1.1 T cells
(19). Recently, results obtained by using Va14-transgenic
mice suggested that selection was the main force in shaping
the NK1.1 T cell repertoire (31). Here we have shown that
in addition to selection, differential Va–Vb pairing can also
potentially influence the NK1.1 T cell diversity. In sum-
mary, our data show that subtle changes in the TCR b chain
conformation (which do not seem to affect conventional
Vb8.21 a/b TCRs) can substantially alter pairing with the
Va141 a chain and impair NK1.1 T cell development.
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